ReviewAnnals of the rheumatic diseases2015
Cardiac troponin testing in idiopathic inflammatory myopathies and systemic sclerosis-spectrum disorders: biomarkers to distinguish between primary cardiac involvement and low-grade skeletal muscle disease activity.
Review in Annals of the rheumatic diseases, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 1 synthesis or guideline pooled it, 93 citations in OpenAlex.
- Cardiac Toxicity Associated with Immune Checkpoint Inhibitors: A Systematic Review.International journal of molecular sciences · 2022Pooled it
- Effect of IL-6 receptor blockade on high-sensitivity troponin T and NT-proBNP in rheumatoid arthritis.Atherosclerosis · 2016Trial
- Cardiac trop T not trop I is a predictor of myocardial injury in idiopathic inflammatory myopathies.Clinical rheumatology · 2026Article
- Case Report: Unusual persistent elevation of troponin I-systemic sclerosis masked by acute myocardial infarction.Frontiers in immunology · 2026Article
- Article
- Idiopathic inflammatory myopathies related lung disease in adults.The Lancet. Respiratory medicine · 2025Review
- Cardiac Involvement in Idiopathic Inflammatory Myopathies.Journal of inflammation research · 2025Review
- Troponin I levels in systemic sclerosis patients with myocardial involvement.Journal of scleroderma and related disorders · 2024Article
- Identification of hub glycolysis-related genes in acute myocardial infarction and their correlation with immune infiltration using bioinformatics analysis.BMC cardiovascular disorders · 2024Article
- Clinical Interpretation of Serum Troponin in the Era of High-Sensitivity Testing.Diagnostics (Basel, Switzerland) · 2024Review
- First study demonstrating speckle tracking echocardiography has prognostic value in patients with idiopathic inflammatory myopathies.The international journal of cardiovascular imaging · 2023Article
- Consensus on the assessment of systemic sclerosis-associated primary heart involvement: World Scleroderma Foundation/Heart Failure Association guidance on screening, diagnosis, and follow-up assessment.Journal of scleroderma and related disorders · 2023Review
- Cardiovascular complications of immune checkpoint inhibitors for cancer.European heart journal · 2022Review
- Immune checkpoint inhibitor-associated myocarditis : Case reports and a review of the literature.Netherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation · 2022Review
- Cardiac damage in autoimmune diseases: Target organ involvement that cannot be ignored.Frontiers in immunology · 2022Review
- Scleromyositis: A distinct novel entity within the systemic sclerosis and autoimmune myositis spectrum. Implications for care and pathogenesis.Frontiers in immunology · 2022Review
- Cardiovascular Abnormalities in Juvenile Dermatomyositis: A Scoping Review for the Clinical Rheumatologists.Frontiers in medicine · 2022Article
- Organ Manifestation and Systematic Organ Screening at the Onset of Inflammatory Rheumatic Diseases.Diagnostics (Basel, Switzerland) · 2021Article
- Idiopathic inflammatory myopathies.Nature reviews. Disease primers · 2021Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
Abstract
Primary cardiac involvement, an under-recognised manifestation of the idiopathic inflammatory myopathies (IIM) and systemic sclerosis (SSc)-spectrum disorders, is associated with significant mortality. Within these two conditions, traditional skeletal muscle enzyme testing may not effectively distinguish between skeletal and cardiac muscle involvement, especially in patients with subclinical cardiac disease. Accurate biomarkers are thus required to screen for cardiac disease, to better inform both therapeutic decision-making and treatment response. The widespread uptake of cardiac troponin testing has revolutionised the management of acute coronary syndromes. While cardiac troponin I (cTnI) appears specific to the myocardium, cardiac troponin T (cTnT) is also expressed by skeletal muscle, including regenerating skeletal muscle tissue. There is increasing interest about the role of cardiac troponins as a putative biomarker of primary cardiac involvement in IIM and SSc-spectrum disorders. Herewith we discuss subclinical cardiac disease in IIM and SSc-spectrum disorders, the respective roles of cTnI and cTnT testing, and the re-expression of cTnT within regenerating skeletal muscle tissue. There remains wide variation in access to cardiac troponin testing nationally and internationally. We propose two pragmatic clinical pathways using cardiac troponins, preferably measuring concomitant cTnT followed by confirmatory (cardiac) cTnI to screen patients for subclinical cardiac disease and/or low-grade skeletal muscle disease activity, and also an agenda for future research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.